2004年本科毕业于华中科技大学同济医学院，同年保送至上海药物所硕博连读，2010年获上海药物所药理学博士学位。随后赴美留学，先后在约翰霍普金斯大学医学院，东北俄亥俄医科大学和贝勒医学院从事博士后研究，主要开展代谢性疾病，例如糖尿病，非酒精性脂肪肝病及动脉粥样硬化的致病机理研究和创新药物开发。2020年引进回国，任中科中山药物创新研究院研究员，课题组长，博士生导师。目前已发表学术论文25篇，包括在Nature Metabolism, Hepatology（2篇）, Arteriosclerosis, Thrombosis, andVascular Biology等代谢领域权威杂志以第一作者发表9篇文章；在 Cell Metabolism, Nature Communications, Diabetes（3篇）以共同作者发表文章16篇。发表文章得到Nature Reviews Endocrinology、Hepatology、Diabetes 等杂志的高度评价和Faculty1000 肝病领域权威专家的推荐。文章总引用超过1100次，H-index 18。新药研发方面，作为主要参与人开发了多个新颖有潜力的代谢性疾病小分子化合物。曾在多个权威国际会议上获得科研奖励，如2016年美国肝病研究协会(AASLD)年会“青年学者奖”及“杰出海报奖”。 2021年入选中国科学院海外高层次人才引进计划、上海市浦江人才、上海市领军人才(海外)等多个人才计划。目前主持包括中科院海外高层次人才引进计划择优资助、上海市浦江人才项目、国家自然科学基金、广东省自然科学基金、中科中山药物创新研究院启动基金等多个科研基金项目。

本实验室针对各种代谢性疾病：非酒精性脂肪肝病、肝纤维化、动脉粥样硬化、炎症性肠病等，开展其致病新机制研究，新靶标发现、确证及新药开发。重点围绕在病理情况下的各种细胞的代谢紊乱通路（如自噬溶酶体，代谢重编程），细胞间及组织间相互通讯紊乱开展新机制的研究。
使用手段：转基因小鼠、基因递送载体、CRISPR-Cas9技术、类器官、代谢组/转录组及蛋白质组学技术。

1. 首次发现肝脏羧酸酯酶CES1, CES2参与非酒精性脂肪肝病致病机理，是新颖的肝脏甘油三酯水解酶，可以作为非酒精性脂肪肝病的治疗靶点。研究成果以第一作者发表于肝病领域权威杂志Hepatology, 2014: 59:1761-1771与Hepatology, 2016:63:1860-1874; 发表文章被当期Hepatology杂志高度评价，得到Faculty1000 Prime 推荐。

2. 首次发现了动脉粥样硬化的新的致病通路: FOXA3-ApoAI, ATF3-p53-SRB1及ATF3-HNF4a-CYP8B1等，阐明此两条通路通过调节逆向胆固醇转运和肠道胆固醇吸收跨器官调节血液胆固醇水平影响动脉粥样硬化发病的机制。相关成果以第一作者发表在代谢领域权威杂志Nature Metabolism, 2021, 3(1):59-74与动脉粥样硬化领域专业杂志Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39(8):1574-1587。

3. 参与开发了多个新颖治疗代谢性疾病的小分子。如糖尿病候选新药开发，参与开发的AMPK 激活剂项目与Roche罗氏中国研发中心合作，已进行系统临床前研究；参与开发的DPPIV抑制剂项目已经拿到临床批件，实现成果转化；相关成果以共同第一作者发表在Toxicol Appl Pharm, 2013:273(2):325-34， ACS Med. Chem. Lett., 2013:4 (5): 475–480，ChemMedChem, 2013:8(7):1104-16， Acta Pharmacologica Sinica, 2010:31:1005–101等。如非酒精性脂肪肝炎NASH候选新药开发，与美国Intercept公司合作，阐明了其公司研发的非酒精性脂肪肝炎三期临床的候选药物奥贝胆酸的降脂机制，相关成果以第一作者发表于Hepatology, 2014: 59:1761-1771。

1.Yanyong Xu#, Yuanyuan Li#, Kavita Jadhav#, Xiaoli Pan, YingdongZhu, Shuwei Hu,  Shaoru Chen, Liuying Chen, Yong Tang, Helen H Wang, LingYang, David Q-H Wang, Liya Yin, Yanqiao Zhang*. Hepatocyte ATF3 protectsagainst atherosclerosis by regulating HDL and bile acid metabolism. NatureMetabolism, 2021, 3(1):59-74(# Co-first author)

2. YuanyuanLi#, Yanyong Xu#, Kavita Jadhav, Liya Yin and Yanqiao Zhang*. Hepaticforkhead box protein A3 regulates ApoA I expression, cholesterol efflux andatherogenesis. Arteriosclerosis, Thrombosis, and Vascular Biology,2019, 39(8):1574-1587(# Co-first author)

3. YuanyuanLi, Munaf Zalzala, Kavita Jadhav, Yang Xu, Takhar Kasumov, Liya Yin andYanqiao Zhang*. Carboxylesterase 2 Prevents Liver Steatosis by ModulatingLipolysis, ER stress and Lipogenesis and is regulated by Hepatocyte NuclearFactor 4 Alpha in Mice. Hepatology, 2016, 63:1860-1874 此研究内容获得2016AASLD肝病会议大会杰出海报奖与优秀年轻学者旅行奖

4.Jiesi Xu #, Yuanyuan Li #, Wei Dong Chen #, Yang Xu #, Liya Yin,Xuemei Ge, Kavita Jadhav, Luciano Adorini, and Yanqiao Zhang*. HepaticCarboxylesterase 1 Is Essential for Both Normal and Farnesoid X ReceptorControlled Lipid Homeostasis. Hepatology, 2014, 59:1761-1771(# Co-first author) 被同期Hepatology 高度评价，Facultyof 1000 推荐

5. YuanyuanLi, Kavita Jadhav, and Yanqiao Zhang*. Bile acid receptors in non-alcoholicfatty liver disease. Biochem Pharmacol, 2013, 86(11):1517-24

6. Yuan-YuanLi#, Li-Fang Yu#, Li-Na Zhang, Bei-Ying Qiu, Ming-Bo Su, Fang Wu, Tao Pang,Min Gu, Wei Zhang, Da-Kai Chen,Wei-Ping Ma, Jing-Ya Li*, Fa-Jun Nan*, Jia Li*.Novel small-molecule AMPK activator orally exerts beneficial effects ondiabetic db/db mice. Toxicol Appl Pharm, 2013, 273(2):325-34(# Co-first author)

7.Li-Fang Yu#, Yuan-Yuan Li#, Ming-Bo Su, Mei Zhang , Wei Zhang ,Li-Na Zhang , Tao Pang , Run-Tao Zhang , Bing Liu , Jing-Ya Li*, Jia Li*, andFa-Jun Nan*. Development of Novel Alkene Oxindole Derivatives As OrallyEfficacious AMP-Activated Protein Kinase Activators. ACS Med. Chem.Lett., 2013, 4 (5): 475–480 (# Co-first author)

8.Linrong Zhu#, Yuanyuan Li#, Qiu Ling, Mingbo Su, Xin Wang, ChunmeiXia, Yi Qu, Jingya Li, Jia Li*, Bin Xiong*, Jingkang Shen*. Design andSynthesis of 4-(2,4,5-Trifluorophenyl)butane-1,3-diamines as DipeptidylPeptidase IV Inhibitors. ChemMedChem, 2013, 8(7):1104-16 (#Co-first author)

9.Zhang Liu#, Qian Chai #, Yuanyuan Li #, Qiang Shen, Lanping Ma*,Lina Zhang, Xin Wang, Li Sheng, Jingya Li, Jia Li*, Jingkang Shen. Discovery ofnovel PTP1B inhibitors with antihyperglycemic activity. ActaPharmacologica Sinica, 2010, 31:1005–1012 (# Co-firstauthor)

10.Michael L. Multhaup, Marcus M. Seldin, Andrew E. Jaffe, Xia Lei, HenrietteKirchner, Prosenjit Mondal, Yuanyuan Li, Varenka Rodriguez,Alexander Drong, Mehboob Hussain, Cecilia Lindgren, Mark McCarthy, ErikNäslund, Juleen R. Zierath, G. William Wong, Andrew P. Feinberg*. Mouse-HumanExperimental Epigenetic Analysis Unmasks Dietary Targets and Genetic Liabilityfor Diabetic Phenotypes. Cell Metabolism, 2015, 21(1):138-49

11.Yang Xu#, Munaf Zalzala#, Jiesi Xu, Yuanyuan Li, Liya Yin, YanqiaoZhang*. A metabolic stress-inducible miR-34a-HNF4α pathwayregulates lipid and lipoprotein metabolism. Nature communications,2015, 6:7466

1.Yanyong Xu#, Yuanyuan Li#, Kavita Jadhav#, Xiaoli Pan, YingdongZhu, Shuwei Hu,  Shaoru Chen, Liuying Chen, Yong Tang, Helen H Wang, LingYang, David Q-H Wang, Liya Yin, Yanqiao Zhang*. Hepatocyte ATF3 protectsagainst atherosclerosis by regulating HDL and bile acid metabolism. NatureMetabolism, 2021, 3(1):59-74(# Co-first author)

2. YuanyuanLi#, Yanyong Xu#, Kavita Jadhav, Liya Yin and Yanqiao Zhang*. Hepaticforkhead box protein A3 regulates ApoA I expression, cholesterol efflux andatherogenesis. Arteriosclerosis, Thrombosis, and Vascular Biology,2019, 39(8):1574-1587(# Co-first author)

3. YuanyuanLi, Munaf Zalzala, Kavita Jadhav, Yang Xu, Takhar Kasumov, Liya Yin andYanqiao Zhang*. Carboxylesterase 2 Prevents Liver Steatosis by ModulatingLipolysis, ER stress and Lipogenesis and is regulated by Hepatocyte NuclearFactor 4 Alpha in Mice. Hepatology, 2016, 63:1860-1874 此研究内容获得2016AASLD肝病会议大会杰出海报奖与优秀年轻学者旅行奖

4.Jiesi Xu #, Yuanyuan Li #, Wei Dong Chen #, Yang Xu #, Liya Yin,Xuemei Ge, Kavita Jadhav, Luciano Adorini, and Yanqiao Zhang*. HepaticCarboxylesterase 1 Is Essential for Both Normal and Farnesoid X ReceptorControlled Lipid Homeostasis. Hepatology, 2014, 59:1761-1771(# Co-first author) 被同期Hepatology 高度评价，Facultyof 1000 推荐

5. YuanyuanLi, Kavita Jadhav, and Yanqiao Zhang*. Bile acid receptors in non-alcoholicfatty liver disease. Biochem Pharmacol, 2013, 86(11):1517-24

6. Yuan-YuanLi#, Li-Fang Yu#, Li-Na Zhang, Bei-Ying Qiu, Ming-Bo Su, Fang Wu, Tao Pang,Min Gu, Wei Zhang, Da-Kai Chen,Wei-Ping Ma, Jing-Ya Li*, Fa-Jun Nan*, Jia Li*.Novel small-molecule AMPK activator orally exerts beneficial effects ondiabetic db/db mice. Toxicol Appl Pharm, 2013, 273(2):325-34(# Co-first author)

7.Li-Fang Yu#, Yuan-Yuan Li#, Ming-Bo Su, Mei Zhang , Wei Zhang ,Li-Na Zhang , Tao Pang , Run-Tao Zhang , Bing Liu , Jing-Ya Li*, Jia Li*, andFa-Jun Nan*. Development of Novel Alkene Oxindole Derivatives As OrallyEfficacious AMP-Activated Protein Kinase Activators. ACS Med. Chem.Lett., 2013, 4 (5): 475–480 (# Co-first author)

8.Linrong Zhu#, Yuanyuan Li#, Qiu Ling, Mingbo Su, Xin Wang, ChunmeiXia, Yi Qu, Jingya Li, Jia Li*, Bin Xiong*, Jingkang Shen*. Design andSynthesis of 4-(2,4,5-Trifluorophenyl)butane-1,3-diamines as DipeptidylPeptidase IV Inhibitors. ChemMedChem, 2013, 8(7):1104-16 (#Co-first author)

9.Zhang Liu#, Qian Chai #, Yuanyuan Li #, Qiang Shen, Lanping Ma*,Lina Zhang, Xin Wang, Li Sheng, Jingya Li, Jia Li*, Jingkang Shen. Discovery ofnovel PTP1B inhibitors with antihyperglycemic activity. ActaPharmacologica Sinica, 2010, 31:1005–1012 (# Co-firstauthor)

10.Michael L. Multhaup, Marcus M. Seldin, Andrew E. Jaffe, Xia Lei, HenrietteKirchner, Prosenjit Mondal, Yuanyuan Li, Varenka Rodriguez,Alexander Drong, Mehboob Hussain, Cecilia Lindgren, Mark McCarthy, ErikNäslund, Juleen R. Zierath, G. William Wong, Andrew P. Feinberg*. Mouse-HumanExperimental Epigenetic Analysis Unmasks Dietary Targets and Genetic Liabilityfor Diabetic Phenotypes. Cell Metabolism, 2015, 21(1):138-49

11. Yang Xu#, Munaf Zalzala#, Jiesi Xu, Yuanyuan Li, LiyaYin, Yanqiao Zhang*. A metabolic stress-inducible miR-34a-HNF4α pathway regulates lipid and lipoprotein metabolism. Naturecommunications, 2015, 6:7466